Bay, A.Öner, A.F.Doǧan, M.Açikgöz, M.Dilek, I.2025-05-102025-05-1020061306-133X2-s2.0-33745750692https://hdl.handle.net/20.500.14720/18068In this study we examined eleven patients with chronic immune thrombocytopenic purpura (ITP) who received anti D retrospectively. All of the cases have Rh+ blood group and non-splenectomized. Anti D was given 30μg/kg/dose on 0, 1, 7, 14, 21, 28 days by intravenous infusion in one hour. Three of them (27%) had complete response, three of them (27%) had partial response, three of them (27%) had minor response, and two of them (18%) didn't response. On following, only one patient who responded initially, had high trombocyte count over 1 year. The other patient's trombocyte counts were decreased to the initial level within 1-3 months after the treatment. We did not observe any important side effect. In conclusion, anti D should be considered as a therapeutic option for childhood chronic ITP.trinfo:eu-repo/semantics/closedAccessAnti DChildIdiopathic Thrombocytopenic PurpuraArticle162Q4Q46366